{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:15:24Z","timestamp":1784240124344,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.tranon.2025.102634","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:08:17Z","timestamp":1767683297000},"page":"102634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Induction chemotherapy with nedaplatin, docetaxel and 5-fluorouracil followed by concurrent nedaplatin and radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A single arm, open label, phase II clinical trial"],"prefix":"10.1016","volume":"64","author":[{"given":"Fang-Zheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4128-8824","authenticated-orcid":false,"given":"Ying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Da","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5554-3726","authenticated-orcid":false,"given":"Jie-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Zhen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao-Xiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Meng","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Quan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-5758","authenticated-orcid":false,"given":"Bin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10192","key":"10.1016\/j.tranon.2025.102634_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.tranon.2025.102634_bib0002","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102634_bib0003","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial","volume":"145","author":"Li","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2025.102634_bib0004","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","article-title":"Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis","volume":"24","author":"Petit","year":"2023","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2025.102634_bib0005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2018.0026","article-title":"NCCN guidelines insights: head and neck cancers, version 1.2018","volume":"16","author":"Colevas","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"11","key":"10.1016\/j.tranon.2025.102634_bib0006","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cac2.12218","article-title":"The Chinese society of clinical oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma","volume":"41","author":"Tang","year":"2021","journal-title":"Cancer Commun."},{"issue":"3","key":"10.1016\/j.tranon.2025.102634_bib0007","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1040-8428(01)00219-0","article-title":"Particular aspects of platinum compounds used at present in cancer treatment","volume":"42","author":"Desoize","year":"2002","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"10.1016\/j.tranon.2025.102634_bib0008","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother Pharmacol."},{"issue":"5","key":"10.1016\/j.tranon.2025.102634_bib0009","first-page":"352","article-title":"Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro","volume":"28","author":"Tanaka","year":"2007","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.tranon.2025.102634_bib0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/CMAR.S35785","article-title":"Nedaplatin: a cisplatin derivative in cancer chemotherapy","volume":"5","author":"Shimada","year":"2013","journal-title":"Cancer Manage Res."},{"issue":"4","key":"10.1016\/j.tranon.2025.102634_bib0011","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(18)30104-9","article-title":"Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II\u2013IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial","volume":"19","author":"Tang","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2025.102634_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38470","article-title":"Effect of concurrent chemoradiotherapy with nedaplatin vs cisplatin on the long-term outcomes of survival and toxic effects among patients with stage II to IVB nasopharyngeal carcinoma: a 5-year follow-up secondary analysis of a randomized clinical trial","volume":"4","author":"Tang","year":"2021","journal-title":"JAMa Netw. Open."},{"issue":"4","key":"10.1016\/j.tranon.2025.102634_bib0013","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(18)30113-X","article-title":"Nedaplatin in nasopharyngeal cancer: the rebirth of platinum salts?","volume":"19","author":"Blanchard","year":"2018","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2025.102634_bib0014","first-page":"2064","article-title":"Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial","volume":"6","author":"Tang","year":"2016","journal-title":"Am. J. Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2025.102634_bib0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jjco\/hyp183","article-title":"Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma","volume":"40","author":"Zheng","year":"2010","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.tranon.2025.102634_bib0016","doi-asserted-by":"crossref","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","article-title":"NCCN Guidelines Insights: antiemesis, Version 2.2017","volume":"15","author":"Berger","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw. J. Natl. Compr. Canc. Netw."},{"issue":"22","key":"10.1016\/j.tranon.2025.102634_bib0017","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1200\/JCO.2008.19.9109","article-title":"Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225","volume":"27","author":"Lee","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2025.102634_bib0018","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.tranon.2025.102634_bib0019","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.2147\/OTT.S103729","article-title":"Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma","volume":"9","author":"Lv","year":"2016","journal-title":"Onco Targets. Ther."},{"issue":"5","key":"10.1016\/j.tranon.2025.102634_bib0020","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(21)00075-9","article-title":"Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III\u2013IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial","volume":"22","author":"Lv","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2025.102634_bib0021","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","article-title":"Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial","volume":"75","author":"Cao","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.tranon.2025.102634_bib0022","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.tranon.2025.102634_bib0023","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S1470-2045(23)00232-2","article-title":"Concurrent chemoradiotherapy followed by adjuvant cisplatin\u2013gemcitabine versus cisplatin\u2013fluorouracil chemotherapy for N2\u20133 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"24","author":"Liu","year":"2023","journal-title":"Lancet Oncol."},{"issue":"3\u20134","key":"10.1016\/j.tranon.2025.102634_bib0024","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000151363","article-title":"Locoregionally advanced nasopharyngeal carcinoma: induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin: a phase II study","volume":"74","author":"Ferrari","year":"2008","journal-title":"Oncology"},{"issue":"11","key":"10.1016\/j.tranon.2025.102634_bib0025","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1093\/annonc\/mdq783","article-title":"Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer","volume":"22","author":"Bossi","year":"2011","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102634_bib0026","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12885-017-3080-4","article-title":"Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial","volume":"17","author":"Ke","year":"2017","journal-title":"BMC. Cancer"},{"issue":"11","key":"10.1016\/j.tranon.2025.102634_bib0027","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JCO.21.01467","article-title":"Deintensified Chemoradiotherapy for pretreatment epstein-barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase ii randomized noninferiority trial","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.tranon.2025.102634_bib0028","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2023.41.16_suppl.6001","article-title":"Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: an open-label, non-inferiority, randomized phase 3 trial","volume":"41","author":"Chen","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.tranon.2025.102634_bib0029","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(15)00305-8","article-title":"Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial","volume":"16","author":"Shukuya","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10297","key":"10.1016\/j.tranon.2025.102634_bib0030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"issue":"10445","key":"10.1016\/j.tranon.2025.102634_bib0031","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325003651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325003651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:51:36Z","timestamp":1784238696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523325003651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"alternative-id":["S1936523325003651"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102634","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction chemotherapy with nedaplatin, docetaxel and 5-fluorouracil followed by concurrent nedaplatin and radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A single arm, open label, phase II clinical trial","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102634"}}